0

Antal anställda

0

Antal patent och patentansökningar

0

Antal biosimilarkandidater under utveckling

Kapitalmarknadsdag 17 maj, 2021


Hemma hos Xbrane Biopharma


Pressmeddelanden

31 Jan 2025

The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.

09 Jan 2025

Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

31 Dec 2024

XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

18 Dec 2024

Xbrane announces outcome of exercise of warrants of series TO1

02 Dec 2024

XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY

26 Nov 2024

Xbrane AB (publ) today announces that the company’s CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.

21 Nov 2024

XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES

19 Nov 2024

Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo®

31 Oct 2024

XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE